Startup Valuation Methods Explained: DCF, Multiples, Backsolve and More

Startup valuation is three different questions wearing one name. What will an investor pay (negotiation)? What number satisfies the law (Companies Act, FEMA, tax – each with its own rulebook)? And what is the equity actually worth for ESOPs and internal decisions (allocation)? Different methods answer different questions: DCF and multiples for the certificates, backsolve and option-pricing for CCPS-heavy cap tables, scorecards and heuristics for angel-stage negotiation. This guide explains each method with the numbers Indian practice actually uses – and which statute accepts which signature.

DCF: the workhorse of Indian certificates

Project free cash flows for five years, discount them, add a terminal value. For startups the terminal value routinely carries 60–80%+ of the total – which is why the discount rate and terminal growth assumption decide the answer. Venture-stage discount rates run far above corporate WACC because they price failure risk: Indian valuers working from the standard venture literature use roughly 50–70% for seed, 40–60% for early stage, 30–50% for growth, and 20–35% pre-IPO, against 12–18% for a mature company. Worked skeleton: FCF of ₹1/2/3/4.5/6 crore over five years at a 25% discount rate gives ₹7.4 crore of explicit-period value; terminal value 6×1.05/(0.25–0.05) = ₹31.5 crore discounts to ₹10.3 crore; with ₹2.25 crore of cash, equity value ≈ ₹20 crore. The legal shield around DCF is now well built: tribunals have repeatedly held that projections are judged by what was reasonable on the valuation date, not by hindsight against actuals – Catwalk Worldwide (ITAT Mumbai, May 2026) deleted a ₹36.5 crore addition on exactly that principle, and the same logic protects FEMA certificates.

Market approaches: multiples and transactions

Comparable company multiples anchor to what the market pays for similar businesses: Indian practice uses EV/Revenue or EV/ARR of roughly 3–10x for SaaS (quality of retention and growth decides where in the band), GMV or revenue multiples for e-commerce, and P/E, P/B or EV/Revenue for fintech (P/B for lending books). Comparable transactions use actual Indian deal prints where they exist. Both suffer the same startup problem – the comparables are rarely comparable – so they usually corroborate a DCF rather than replace it. The clean exception is the backsolve: when the company itself just closed a round, that price is the best market evidence available, and the method built on it deserves its own section.

Backsolve and option-pricing: valuing equity under a preference stack

A ₹500 CCPS price does not mean the equity shares are worth ₹500 – the CCPS carries a liquidation preference and anti-dilution the equity does not. The option-pricing method (OPM) treats each class as a call option on total equity value, with breakpoints at the preference and conversion thresholds, and the backsolve runs it in reverse: find the total equity value at which the model prices the new CCPS at exactly what investors just paid. Worked sketch: a ₹50 crore Series A at ₹500/CCPS (headline post-money ₹250 crore) backsolves – with 60% volatility, a 3-year horizon – to total equity value near ₹175 crore; the common-share allocation lands around ₹310, and after a typical 25% discount for lack of marketability the equity FMV is ≈ ₹235, about 47% of the preferred price. That 30–60% common-to-preferred ratio is the practical norm – and it is the number that keeps ESOP exercise perquisites moderate, which is why backsolve-OPM is the standard for merchant-banker ESOP valuations under Rule 15. Its siblings – milestone analysis (value tied to discrete de-risking events) and PWERM (probability-weighted exit scenarios, best near an exit) – entered Indian statute briefly via the 2023 angel-tax rules; with those rules gone, all three survive as best practice for FEMA certificates and equity allocation rather than as tax mandates (see the valuation rules guide).

Angel-stage heuristics: honest rules of thumb

MethodMechanics in one lineUse
ScorecardStart from the median pre-money of comparable regional seed deals; adjust by weighted factors (team ~30%, market ~25%, product ~15%, competition, traction…)The most defensible angel heuristic
BerkusAssign value per de-risking element – idea, prototype, team, relationships, early sales – India-adapted practice uses roughly ₹1–2 crore per elementPre-revenue sanity cap
VC methodExit value ÷ target return (10–30x, or a 40–60% IRR) – investment = pre-moneyShows the investor’s arithmetic
Risk-factor summationBase value adjusted up/down across ~12 named risksCross-check

None of these signs a certificate; all of them anchor the negotiation covered in the angel round guide. When an angel round needs paper – a priced CCPS issue – the registered valuer or CA behind the certificate will translate the negotiated number into a DCF or market-approach rationale.

Which statute accepts which method (and whose signature)

PurposeMethod regimeSignature
FEMA Rule 21 certificateAny internationally accepted methodology, arm’s length – DCF dominatesCA / merchant banker / cost accountant
Companies Act preferential-issue priceRegistered valuer’s professional judgment (ICAI Valuation Standards 101–303 for RVO members)Registered valuer only
s.92 / s.79 income-tax FMVRule 57 NAV formula only for unquoted equity; open-market for CCPS/other securitiesComputational; MB or accountant support
ESOP perquisite (Rule 15)Merchant banker’s FMV – backsolve-OPM standardMerchant banker only, 180-day window
Cross-border swaps (Rule 9A)As certifiedMerchant banker / overseas investment banker only
The one-number fallacy: a funding round can legitimately produce three different values on the same day – ₹820 (deal price), ₹800 (DCF certificate), ₹235 (backsolved equity FMV for ESOPs) – and all three are correct, because they answer different questions under different rules. Trouble starts when a document quotes the wrong number for its statute: an ESOP scheme priced off the preferred price overstates perquisite tax threefold; a FEMA certificate quoting the backsolved equity value understates the floor. Label every number with its purpose.

Need the right number for the right statute?

My Cloud Accountant coordinates DCF certificates, registered-valuer reports and merchant-banker ESOP valuations – consistent assumptions, correct signatures, one file.

Talk to an expert

Frequently Asked Questions

Which valuation method gives the highest number?

Wrong question – methods answer different purposes. For negotiation, comparables in a hot sector run highest; DCF is as high as its assumptions; NAV is almost always lowest for a startup. Investors triangulate; certificates must justify, not maximise.

Is a valuation done for the last round reusable for this round?

Rarely. FEMA practice expects certificates within ~90 days of the transaction; the ESOP rule allows a 180-day window from its specified date; and a new round’s terms change the backsolve inputs entirely. Budget for fresh reports per event – they are cheap against the risks they retire.

Why is our ESOP valuation so much lower than our round price?

Because it should be: the round price buys CCPS with a liquidation preference and other protections; the ESOP values plain equity under that stack, discounted further for non-marketability. A 30–60% ratio of equity FMV to preferred price is normal – and it is your employees’ tax advantage, not an error.

What happens if the projections in our DCF turn out wrong?

Nothing, if they were honest when made – tribunals consistently refuse to test valuation-date projections against later actuals (Catwalk Worldwide, ITAT Mumbai 2026, is the latest). What sinks valuations is internal inconsistency – projections contradicting the board’s own contemporaneous documents. Keep the assumptions file.

Last reviewed: August 2026. ICAI Valuation Standards 101–303; Income-tax Rules 2026 (Rules 15, 56–57); FEM (NDI) Rules 2019 Rule 21; discount-rate and multiple ranges reflect published venture-valuation literature and Indian market practice – engagement-specific numbers vary.

General information, not a valuation opinion. Method selection and assumptions must be set by the signing professional for your specific facts.
Scroll to Top